Navigation Links
PharMEDium Supports Draft Legislation, Efforts to Strengthen Oversight of the Compounding Industry
Date:4/26/2013

WASHINGTON, April 26, 2013 /PRNewswire/ -- PharMEDium is encouraged by the progress made today by the twelve bipartisan Members of the Senate Health, Education, Labor, and Pensions (HELP) Committee toward assuring the highest level of safety possible for patients who receive sterile compounded preparations. The Senate HELP Committee has produced a detailed and thoughtful Bill which goes a long way toward addressing the complicated but crucial question of how to improve regulatory oversight of this vital sector of the pharmacy industry. 

PharMEDium, the nation's leading provider of sterile admixture preparations for hospitals throughout the country, supports the proposed new category of "compounding manufacturer," federal oversight and inspections of these facilities to applicable cGMP standards. While we recognize this is the beginning of a lengthy legislative process, we encourage those in our industry to join us in supporting these efforts to achieve and maintain the highest quality of safety for users of sterile preparations. PharMEDium has long advocated for increased FDA authority and oversight of the sterile compounding process and looks forward to working with the Committee and Members of Congress on the further development and passage of this important legislation.

Who we are: PharMEDium is one of the nation's leading providers of hospital pharmacy-outsourced, sterile admixture services with centers in four states and thousands of acute care hospital customers nationwide. Our qualified personnel and state-of-the-art centers are registered with the FDA, licensed by states as compounding pharmacies and governed by our own rigorous quality standards. We begin the compounding process with sterile FDA-approved drugs from FDA-approved drug manufacturers. It is our mission to be the preeminent provider of choice for hospital customers and to attain the highest degree of integrity in the compounding of sterile preparations.Contact:

Bob Szafranski Bob.Szafranski@edelman.com312-863-9135 (mobile)312-240-2687 (work)


'/>"/>
SOURCE PharMEDium
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo
2. PharMEDium Encourages Swift Action to Strengthen Federal Oversight of Advanced Sterile Compounding
3. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
4. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
5. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
6. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
7. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
8. Ventana Supports World Patient Safety Day, July 25
9. eCardio Supports the Carolinas HealthCare Foundation Through Grant for Heart Of A Champion Day
10. Verify Brand Supports the Proposed FDA Unique Device Identification (UDI) System for Medical Devices
11. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)... -- Sickle cell disease (SCD) is an inherited chronic ... get stuck in veins and block blood flow, which ... leading to death. Each year, approximately 300,000 people around ... them lack access to comprehensive care or effective treatment ... SCD, a pill called hydroxyurea approved more than a ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology:
(Date:12/4/2016)... NY (PRWEB) , ... December 03, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted its first Swirl: A Wine Tasting Event in New York City, ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... ... undergoing major cosmetic surgery can now take advantage of a cosmetic procedure known ... skin rejuvenation treatment that reduces the appearance of age spots, fine lines, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
Breaking Medicine News(10 mins):